Payment overview · 2025
General Payments
$122.17
1 reported records · 1 companies
Healthcare provider profile · identity verified
Evlyn Avanessian, M.D
Allopathic & Osteopathic Physicians|Family Medicine · LA CRESCENTA, CA · NPI 1295020709
Verified facts
What the public records show
CMS Open Payments records show Evlyn Avanessian, M.D received $122.17 in general payments during 2025 across 1 reported records.
Amgen Inc. accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $122.17 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $122.17 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 496 | 97 |
| Gabapentin | Gabapentin | 387 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 70 |
| Losartan Potassium | Losartan Potassium | 305 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 268 | 47 |
| Metformin Hcl | Metformin Hcl | 234 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 56 |
| Carvedilol | Carvedilol | 220 | 42 |
| Jardiance | Empagliflozin | 216 | 35 |
| Tradjenta | Linagliptin | 208 | 20 |
| Sertraline Hcl | Sertraline Hcl | 193 | 30 |
| Vascepa | Icosapent Ethyl | 180 | 30 |
| Lisinopril | Lisinopril | 179 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 178 | 52 |
| Eliquis | Apixaban | 163 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 75 |
| Omeprazole | Omeprazole | 155 | 35 |
| Trazodone Hcl | Trazodone Hcl | 126 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 29 |
| Meloxicam | Meloxicam | 111 | 60 |
| Memantine Hcl | Memantine Hcl | 111 | 18 |
| Ezetimibe | Ezetimibe | 110 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 17 |
| Donepezil Hcl | Donepezil Hcl | 95 | 18 |
| Januvia | Sitagliptin Phosphate | 94 | 13 |
| Baclofen | Baclofen | 91 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 14 |
| Famotidine | Famotidine | 90 | 22 |
| Icosapent Ethyl | Icosapent Ethyl | 90 | 24 |
| Furosemide | Furosemide | 87 | 28 |
| Allopurinol | Allopurinol | 82 | 15 |
| Ozempic | Semaglutide | 77 | 13 |
| Potassium Chloride | Potassium Chloride | 76 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 71 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 15 |
| Lorazepam | Lorazepam | 69 | 11 |
| Alendronate Sodium | Alendronate Sodium | 68 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 14 |
| Mirtazapine | Mirtazapine | 66 | 12 |
| Azithromycin | Azithromycin | 65 | 57 |
| Linzess | Linaclotide | 64 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 62 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 33 |
| Metformin Hcl Er | Metformin Hcl | 56 | 17 |
| Finasteride | Finasteride | 55 | 11 |
| Glipizide | Glipizide | 54 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 11 |
| Atenolol | Atenolol | 51 | suppressed |
| Sucralfate | Sucralfate | 51 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | suppressed |
| Lactulose | Lactulose | 49 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Methimazole | Methimazole | 48 | suppressed |
| Ketoconazole | Ketoconazole | 46 | 19 |
| Celecoxib | Celecoxib | 45 | 13 |
| Meclizine Hcl | Meclizine Hcl | 45 | 16 |
| Clonidine Hcl | Clonidine Hcl | 44 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 12 |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 35 |
| Simvastatin | Simvastatin | 42 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Colchicine | Colchicine | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 15 | 11 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.17 · 1 records | Amgen Inc. | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error